<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03980509</url>
  </required_header>
  <id_info>
    <org_study_id>103089</org_study_id>
    <nct_id>NCT03980509</nct_id>
  </id_info>
  <brief_title>A &quot;Window Trial&quot; on Curcumin for Invasive Breast Cancer Primary Tumors</brief_title>
  <official_title>A &quot;Window Trial&quot; on Curcumin, the Active Compound in Turmeric, for Invasive Breast Cancer Primary Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether oral administration of curcumin causes
      biological changes in primary tumors of breast cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether oral administration of Curcuma longa
      extract causes biological changes related to apoptosis (DNA fragmentation) and cell
      proliferation (Ki67) in primary tumors of breast cancer patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in tumor proliferation rate</measure>
    <time_frame>Up to 56 days</time_frame>
    <description>Change in tumor proliferation rate will be based on apoptosis (DNA fragmentation) and cell proliferation (Ki67) assays in biopsies pre and post treatment with curcumin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events reported</measure>
    <time_frame>up to 84 days</time_frame>
    <description>Safety data will be tabulated by type and grade of adverse event and will use CTCAE v. 4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Curcumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Curcumin will be given at 500mg by mouth twice a day, immediately after each meal. Curcumin will be given from the time surgical resection is scheduled until the night before surgical resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>Curcumin is an extract from turmeric</description>
    <arm_group_label>Curcumin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed invasive breast cancer (stages I, II, or III) with primary
             tumor(s) â‰¥ 1.0 cm on mammogram, ultrasound, MRI, or physical exam

          2. 18 years of age or older

          3. Subject must understand risks and benefits of the protocol and be able to give
             informed consent

          4. Women of childbearing potential (WOCBP) must agree to use an approved form of birth
             control and to have a negative pregnancy test result within 14 days of registration.
             WOCBP is defined as any female who has experienced menarche and who has not undergone
             surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not
             postmenopausal. Menopause is defined clinically as 12 consecutive months of amenorrhea
             in a woman over 45 in the absence of other biological or physiological causes

             Approved forms of birth control:

               -  combined (estrogen and progestogen containing) hormonal contraception associated
                  with inhibition of ovulation (oral, intra-vaginal, or transdermal)

               -  progestogen only hormonal contraception associated with inhibition of ovulation
                  (oral, injectable, or implantable)

               -  intrauterine device, intrauterine hormone-releasing system

               -  bilateral tubal occlusion/ligation

               -  vasectomized partner

               -  barrier contraception

               -  sexual abstinence

          5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          6. Adequate hematologic and end organ function

          7. Ability and capacity to comply with the study and follow-up procedures

          8. Subjects must be scheduled for surgery at MUSC no less than 5 days from the planned
             start of day 1 and no more than 56 days from the planned start of day 1

          9. At least 6 sections of unstained slides should be obtained. If sufficient slides or
             tissue is unavailable, the patient will be excluded from the trial

        Exclusion Criteria:

          1. Subjects undergoing neoadjuvant chemotherapy or neoadjuvant endocrine therapy

          2. Subjects with end-stage kidney disease and/or grade II liver dysfunction

          3. Subjects who are pregnant or are lactating.

          4. Subjects with bile duct obstruction, gallstones, predisposition to kidney stones(39),
             or gastrointestinal disorders such as stomach ulcers and hyperacidity disorders(40)

          5. Subjects taking anti-coagulants or platelet inhibitors

          6. Subjects taking drugs metabolized by CYP3A4, CYP1A2, and CYP2A6 enzymes

          7. Subjects taking drugs that interact with P-glycoprotein (P-gp)

          8. Subjects taking any of the medications listed under Other Herb-Drug interactions
             according to the Memorial Sloan Kettering Cancer Center in section 5.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy DeMore, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Green</last_name>
      <phone>843-792-7573</phone>
      <email>hcc-clinical-trials@musc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

